
Capricor Therapeutics Inc. (CAPR) shares slumped sharply after spiking prior to market open. Shares of the stock were up due to the company highlighting a report detailing significant improvements for muscular dystrophy patients treated with the company’s cell therapy. However, it was noted shortly thereafter by some traders that the report was published back in the first half of 2017, so the market was already aware of this information. Here’s a recap of the action.